Related references
Note: Only part of the references are listed.Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS
Elena Tsourdi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Are drug holidays a safe option in treatment of osteoporosis? - Insights from an in silico mechanistic PK-PD model of denosumab treatment of postmenopausal osteoporosis
Javier Martinez-Reina et al.
JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS (2021)
Effect of nitrogen-containing bisphosphonates on osteoclasts and osteoclastogenesis: an ultrastructural study
Yoshitoki Takagi et al.
MICROSCOPY (2021)
Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
Athanasios D. Anastasilakis et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption
Michelle M. McDonald et al.
CELL (2021)
Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases
Peter Burckhardt et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2021)
Combined Effects of Exercise and Denosumab Treatment on Local Failure in Post-menopausal Osteoporosis-Insights from Bone Remodelling Simulations Accounting for Mineralisation and Damage
Javier Martinez-Reina et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)
Bone Mineral Density After Transitioning From Denosumab to Alendronate
David Kendler et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider
Liana Tripto-Shkolnik et al.
BONE (2020)
Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis A Population-Based Cohort Study
Houchen Lyu et al.
ANNALS OF INTERNAL MEDICINE (2020)
Establishment of a Disease-Drug Trial Model for Postmenopausal Osteoporosis: A Zoledronic Acid Case Study
Yi Ting (Kayla) Lien et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Mechanobiological osteocyte feedback drives mechanostat regulation of bone in a multiscale computational model
Madge Martin et al.
BIOMECHANICS AND MODELING IN MECHANOBIOLOGY (2019)
Effects of long-term treatment of denosumab on bone mineral density: insights from an in-silico model of bone mineralization
Javier Martinez-Reina et al.
BONE (2019)
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study
M. B. Zanchetta et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis
Albrecht Werner Popp et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis
Athanasios D. Anastasilakis et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
The Quest for Osteoporosis Mechanisms and Rational Therapies: How Far We've Come, How Much Further We Need to Go
Stavros C. Manolagas
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
Athanasios D. Anastasilakis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Observations following discontinuation of long-term denosumab therapy
M. R. McClung et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Osteoporosis: the evolution of a diagnosis
M. Lorentzon et al.
JOURNAL OF INTERNAL MEDICINE (2015)
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
S. Papapoulos et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone
Xiaolin Tu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone
Jinhu Xiong et al.
PLOS ONE (2015)
A Tutorial on Target-Mediated Drug Disposition (TMDD) Models
P. Dua et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2015)
Osteocytes: Master Orchestrators of Bone
Mitchell B. Schaffler et al.
CALCIFIED TISSUE INTERNATIONAL (2014)
For whom the bell tolls: Distress signals from long-lived osteocytes and the pathogenesis of metabolic bone diseases
Stavros C. Manolagas et al.
BONE (2013)
Coupling systems biology with multiscale mechanics, for computer simulations of bone remodeling
Stefan Scheiner et al.
COMPUTER METHODS IN APPLIED MECHANICS AND ENGINEERING (2013)
Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Application of a mechanism-based disease systems model for osteoporosis to clinical data
Teun M. Post et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2013)
Predicting Nonlinear Changes in Bone Mineral Density Over Time Using a Multiscale Systems Pharmacology Model
M. C. Peterson et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2012)
Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women
Dhananjay D. Marathe et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2011)
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Evidence for osteocyte regulation of bone homeostasis through RANKL expression
Tomoki Nakashima et al.
NATURE MEDICINE (2011)
A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling
Mark C. Peterson et al.
BONE (2010)
A bone remodelling model including the directional activity of BMUs
J. Martinez-Reina et al.
BIOMECHANICS AND MODELING IN MECHANOBIOLOGY (2009)
Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL
Paul J. Kostenuik et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Osteoclast-osteoblast communication
Koichi Matsuo et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2008)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
Model structure and control of bone remodeling: A theoretical study
Peter Pivonka et al.
BONE (2008)
On the role of bone damage in calcium homeostasis
J. Martinez-Reina et al.
JOURNAL OF THEORETICAL BIOLOGY (2008)
Seasonal change in osteoid thickness and mineralization lag time in ambulant patients
Allan G. Need et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
A bone remodelling model coupling microdamage growth and repair by 3D BMU-activity
JM García-Aznar et al.
BIOMECHANICS AND MODELING IN MECHANOBIOLOGY (2005)
Tensile yield in compact bone is determined by strain, post-yield behaviour by mineral content
JD Currey
JOURNAL OF BIOMECHANICS (2004)
Modeling the interactions between osteoblast and osteoclast activities in bone remodeling
V Lemaire et al.
JOURNAL OF THEORETICAL BIOLOGY (2004)
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis
JM Halasy-Nagy et al.
BONE (2001)
Share Paper
